AC Immune
Greg del Val is an experienced professional in the field of biopharmaceuticals, with a focus on antibody engineering and the blood-brain barrier. Currently serving as an expert in this area at AC Immune, Greg has held several significant roles, including Senior Research Scientist. Prior to this, Greg was Head of Bioanalytics and Project Leader at AB2 Bio. Experience also includes positions as Technical Specialist and Scientific Leader at Syngenta Biopharma, as well as Senior Scientist and Project Leader roles at both Diversa and Torrey Mesa Research Institute.
This person is not in any teams
AC Immune
3 followers
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.